Medicine and Dentistry
Acute Myeloid Leukemia
100%
Diffuse Large B-Cell Lymphoma
92%
Malignant Neoplasm
87%
Overall Survival
80%
Personalized Medicine
50%
Cancer Staging
50%
Pancreas Cancer
50%
Gemcitabine
50%
Non Small Cell Lung Cancer
50%
Immune Checkpoint Inhibitor
50%
Systematic Review
50%
Homologous Recombination
50%
Socioeconomic Status
50%
Solid Malignant Neoplasm
50%
Patient Registry
50%
Targeted Therapy
50%
Lymphocyte
50%
Gene Expression Profiling
50%
Gene Expression
50%
Venetoclax
50%
Induction Chemotherapy
50%
Clustered Regularly Interspaced Short Palindromic Repeat
50%
Cas9
50%
DNA Damage Response
50%
Cisplatin
50%
Atrial Fibrillation
50%
Apoplexy
50%
Multiple Myeloma
42%
Neoplasm
40%
Clinical Trial
28%
Combination Chemotherapy
25%
Biological Marker
24%
Hazard Ratio
21%
Minimal Residual Disease
16%
Sex Difference
16%
Programmed Death-Ligand 1
14%
Liver Metastasis
14%
Immunohistochemistry
14%
Epileptic Absence
14%
Tumor Biopsy
12%
Lung Cancer
12%
Drug Prescription
12%
Oncology
12%
Drug Administration
12%
Prostate Cancer
12%
Cancer Localization
12%
Molecular Profiling
12%
Progression Free Survival
12%
Monotherapy
10%
B Cell Lymphoma Cell
9%
Allogeneic Stem Cell Transplantation
8%
Retrospective Study
8%
Recurrence Free Survival
8%
Selection Bias
8%
Attributable Risk
8%
Antithrombotic
8%
Anticoagulant Therapy
8%
Thromboembolism
8%
Immunocompetent Cell
7%
Proportional Hazards Model
7%
Biopsy
7%
Dendritic Cell
7%
Cohort Analysis
7%
Cell Count
7%
Diseases
7%
Observational Study
7%
Quality of Life
5%
Circulating Tumor DNA
5%
Frailty
5%
Phase II Trials
5%
Randomized Controlled Trial
5%
Post-Hoc Analysis
5%
Electrocorticography
5%
Colorectal Cancer
5%
Interleukin-6
5%
Drug Therapy
5%
Recommended Drug Dose
5%
Keyphrases
Substantial Clinical Benefit
50%
Late-stage Cancer
50%
Denmark
50%
Deficiency Detection
50%
Treatment Trajectory
50%
Treatment Lines
50%
Danish National Patient Registry
50%
Systemic Anti-cancer Treatment
50%
Solid Tumors
50%
Tumor Patients
50%
Nab-paclitaxel
50%
Relapsed or Refractory Acute Myeloid Leukemia
50%
Exhaled Breath Biomarkers
50%
CRISPR-Cas9 Knockout
50%
Cisplatin Response
50%
Knockout Screen
50%
Stroke Risk
50%
Female Patients
50%
Atrial Fibrillation
50%
Male Patients
50%
National Cohort Study
50%
Molecular Tumor Board
37%
F1 Score
37%
Positional Variation
37%
Inter-fraction
25%
Long-course Radiotherapy
25%
Sex Differences
25%
ERCC6
22%
On-premises Software
16%
Address Sharing
16%
Dataverse
16%
Address Data
16%
Platinum Drugs
16%
Absolute Lymphocyte Count
12%
End-stage Cancer
12%
Druggability
12%
Aalborg
12%
Overfitting
12%
Epidemiological Study
12%
Low LDL Cholesterol
12%
Genotype-Tissue Expression (GTEx)
12%
PCSK9 Expression
12%
Patient Treatment
12%
Drug Administration
12%
Consecutive Patients
12%
Oncology
12%
Cancer Site
12%
Registry Data
12%
Matching Strategy
12%
University Hospital
12%
Prescription Drugs
12%
Hierarchical Linear Mixed Model
12%
Positional Change
12%
Precision Radiotherapy
12%
Mesorectum
12%
Risk Difference
12%
Risk Estimation
12%
Risk Score
12%
Stroke Risk Factors
12%
Risk Modifiers
12%
Time Trends
12%
Female Sex
12%
Atrial Fibrillation-related Stroke
12%
Adjusted Relative Risk
12%
Thromboembolic Risk
12%
Oral Anticoagulant Therapy
12%
Comorbid
12%
Relapsed or Refractory
11%
Cisplatin Sensitivity
11%
Primary Refractory
8%
Low SES
7%
Group Disparities
7%
Peripheral Immune Cells
6%
NCounter
6%
JAK-STAT
6%
Resistance Biomarkers
5%
Personalized Allocation
5%
Gemcitabine Monotherapy
5%
Nucleotide Excision Repair
5%
Cell Cycle Distribution
5%
Human Exhaled Breath
5%
SFTPA2
5%
PEBP1
5%
PSMA4
5%
CFL1
5%
ALDOA
5%
Biochemistry, Genetics and Molecular Biology
Myeloid
57%
Lymphocyte Count
50%
Overall Survival
50%
Gene Expression Profiling
50%
Gene Expression
50%
Lipid
50%
Genome-Wide Association Study
50%
Immune Checkpoints
50%
PCSK9
50%
B Cell
42%
ERCC6
20%
XPA
20%
Cholesterol Blood Level
20%
Lipid Level
20%
PD-L1
14%
Triglyceride
10%
Apolipoprotein B
10%
Genetic Divergence
10%
Genetic Architecture
10%
Population Research
10%
Regulatory Element
10%
Blood Lipids
10%
HDL-Cholesterol
10%
Lipid Homeostasis
10%
Apolipoprotein A1
10%
Dendritic Cell
7%
Progression Free Survival
7%
Immunocompetent Cell
7%
Comorbidity
7%
Observational Study
7%
Cell Count
7%
Cohort Study
7%
Ibrutinib
5%
Nucleotide Excision Repair
5%
SFTPA2
5%